Linda Ji has extensive experience representing U.S. and international companies in connection with a wide range of domestic and cross-border corporate and commercial transactions, with a specialty focus on deals between China and the United States. Linda represents clients ranging from startups to Fortune 500 companies in various industries, including emerging and high technologies, life sciences, consumer products, manufacturing and health care real estate.
Linda develops strategies and practical solutions tailored to each client, taking into consideration their unique needs, laws and regulations of China, U.S. and other jurisdictions, as well as tax treaties.Linda organizes and leads customized legal teams to meet clients’ needs in multiple areas, including corporate, securities, tax, export control, labor and employment, immigration, intellectual property, regulatory, and real estate areas.
Linda has represented multiple Chinese and U.S. companies in a variety of transactions in the US, including corporate structuring, new company formation, equity investments, venture capital financing, debt financings, mergers and acquisitions, IPOs and post-IPO compliance, joint ventures, technology licensing, strategic collaborations, as well as corporate governance, equity compensation and equity incentive plans, and other operational matters. Linda counsels China-based clients in connection with transactions involving US national security analysis, prepare and submit filings with the Committee on Foreign Investment in the United States (CFIUS), and have dialogues with CFIUS.
Additionally, Linda advises US and European companies on doing business in China, on matters such as formation of wholly owned subsidiaries or joint ventures, acquisitions, compliance, IP enforcement and profits repatriation.
Prior to coming to the US, Linda worked at the Ministry of Commerce of PR China (MOFCOM) in Beijing. At MOFCOM, she participated in negotiating bilateral treaties between China and other countries concerning reciprocal protection of private investments, reviewing foreign investment projects and drafting laws and regulations concerning foreign investments in China.
Represent a selling shareholder in the process of the initial public offering (IPO) of Best, Inc. which raised $450 million.
Represent an international medical device company in connection with its proposed acquisition of the microsphere business (the high-value interventional oncology segment) from Boston Scientific valued at approximately $100M.
Represent a corporate venture fund in an investment in an early stage medical device company.
Represent a U.S. biotech company in connection with its Series A and Series B financings and structuring the establishment of an affiliated entity in China.
Represent a U.S. biotech company in connection with the CFIUS analysis with respect to its proposed seed round financing and Series A round financing.
Represent a China public company in connection with its proposed acquisition of a U.S. clinical research business.
Represent the U.S. subsidiary of VcanBio Cell & Gene Engineering Co., Ltd., a leading Chinese life science company, in connection with its expansion in the U.S., including setting up several additional subsidiaries, an R&D center, collaboration and licensing arrangements, office building purchases, investments and acquisitions.
Represent a $30M corporate venture fund in connection with its fund formation and its investments in four portfolio companies in the U.S.
Represent a U.S. startup company in corporate restructuring, two rounds of VC financings and putting into place a VIE structure.
Represent several Chinese life sciences companies in connection with setting up their U.S. operating and R&D centers in Massachusetts.
Represent a U.S. life sciences early stage company in connection with a proposed financing and licensing deal with a large pharmaceutical company.
Represent a Chinese company in connection with its acquisition of 100% equity of a U.S. carbon composite materials manufacturer.
Represent prominent Chinese investors, Cindat Capital Management and Union Life Insurance, in the US$930 million purchase of a health care real estate portfolio consisting of 39 senior housing and assisted living facilities throughout 11 states in the United States from Welltower Inc., a health care real estate investment trust (REIT)*
Represent a leading China-based asset management company in connection with $50M investment in a US medical device company
Represent a leading China-based asset management company in connection with $125M convertible note financing to a real estate project located in New York City*
Represent a leading Chinese investment company in connection with its $100M proposed acquisition of a NASDAQ-listed biotechnology company*
Represent a biopharmaceutical company in connection with its initial public offering (IPO) and post-IPO compliance and reporting work*
Represent many U.S. companies in connection with stock purchases, asset purchases, mergers and management buyout*
Represent many start-up companies in connection with company formation, corporate restructuring, equity incentive plans and venture capital financings*
Represent many U.S. and Cayman Islands venture capital and private equity funds in their investments in US and Chinese companies*
New England Chinese Information and Network Association (NECINA)
St. Louis University School of Law, JD, magna cum laude
St. Louis University School of Law, LLM, magna cum laude
University of International Business and Economics School of Law, LLB, Outstanding Graduate Award
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.